ECE2023 Eposter Presentations Thyroid (128 abstracts)
Bone metastases of differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series
Ana Piñar Gutiérrez 1 , Ana R. Romero-Lluch 1 , Suset Dueñas Disotuar 1 , Irene De Lara-Rodriguez 1 , Maria Angeles Galvez Moreno 2 , Tomas Martin Hernandez 3 , Jorge Garcia Aleman 4 , Guillermo Martínez-de Pinillos 5 , Carolina Sánchez-Malo 6 & Elena Navarro 1
1Virgen del Rocío University Hospital, Sevilla, Spain; 2Hospital Universitario Reina Sofia, Córdoba, Spain; 3Hospital Universitario Virgen Macarena, Sevilla, Spain; 4Hospital Universitario Virgen de la Victoria, Málaga, Spain; 5Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain; 6Hospital of Jaen, Jaén, Spain
Objective: To describe the characteristics, survival and prognostic factors of a cohort of patients with bone metastases (BM) of differentiated thyroid carcinoma (DTC).
Methods: Multicenter retrospective observational study. Patients diagnosed with DTC and BM between 1980-2021 were included. A Cox regression was performed to study prognostic factors for 5- and 10-year survival. Kaplan-Meier and log-rank tests were performed for survival analysis and comparison between groups.
Results: n=63. Follow-up=35(15-68)months. 30(48.4%) presented with BM at the initial DTC evaluation. 38(60.3%) had papillary variant. 32(50.8%) presented multiple BM. The most frequent location was the spine (60.3%). Other metastases were present in 77.8%, mainly pulmonary (69.8%). 54(85.9%) received treatment with I131, with BM uptake in 31(49.2%). 25(39.7%) received treatment with multikinase inhibitors. 34(54%) presented skeletal related events. 34(54%) died. 5- and 10-year survival was 42.4% and 20.4% respectively. Significant prognostic factors in multivariate analysis were the presence of N1 (HR 2.916 (95% CI 1.013-8.391);P=0.047) and treatment with I131 (HR 0.214 (95% CI 0.069-0.665);P=0.008) at 5 years; and the presence of other metastases (HR 6.844 (95% CI 1.017-46.05);P=0.048) and treatment with I131 (HR 0.23 (95% CI 0.058-0.913);P=0.037) at 10 years.
Conclusions: Our study reflects the management of patients with BM of DTC in real clinical practice in several centers in southern Spain. The use of antiresorptive drugs was lower than recommended based on current evidence on their preventive role in SRE. Overall survival at 5 and 10 years was lower in patients who were not treated with I131, had nodal involvement and/or had other metastases.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more